



PRESS RELEASE

innate pharma®

INNATE PHARMA ADDS NEW BOARD MEMBERS

Philippe Pouletty and Bernard Malissen bring international business and scientific expertise to innate immunity company

Marseille, octobre, 2001

The arrival of Dr Pouletty, founder of several public biotech companies, and Dr Malissen, one of Europe's pioneers in molecular immunology, is a further demonstration of Innate Pharma's commitment to use the best advisers at each stage of its development, the company said. The new board members will help the company in several important next steps in 2002 including the start of clinical trials for Phosphostim and Innacell- $\gamma\delta$ (both products based on the stimulation of non-conventional lymphocytes), and a second round of financing.

Philippe Pouletty, MD, 43, is an immunologist and graduate of Pasteur Institute and former resident in Paris Hospitals. He was a Stanford University researcher and founder of several biotechnology companies in North America and France, including DrugAbuse Sciences (still privately held), ConjuChem (CJC - Toronto SE) and SangStat (SANG - Nasdaq) Dr Pouletty is a member of the Immunology Society of France, the author of many scientific publications and the holder of a number of patents in the field of immunology and drug discovery. He is also a founder and general partner of the Truffle Venture fund. His position as president of France Biotech, France's industry association, gives him an unparalleled view of national and international developments in biotechnology.

"Innate Pharma is based on ground-breaking science with significant potential for novel therapies," said Dr Pouletty. "I am delighted to serve on the board of Innate and help the company develop its R&D and business strategy."

Bernard Malissen, PhD, 48 is an immunologist and director of the Immunology Centre of Marseille-Luminy (CIML), run by France's leading research institutes, INSERM and the CNRS. A pioneer in molecular immunology in Europe, his research has centered on antigen recognition and the activation of T-cells, as well as T-cell genetics. His work in these fields earned him the CNRS silver medal as well as many international awards. Dr Malissen is already chairman of the scientific advisory board of Innate Pharma.

"Innate Pharma has chosen an area of science that has not yet realized its full potential and which I am convinced will lead to several novel therapies," said Malissen. "I am delighted to contribute to the development of the company."

"We are extremely pleased to have the commitment of these two experienced players in the immunology and biotechnology fields," said Hervé Brailly, CEO of Innate Pharma. "Philippe, as a 'serial entrepreneur' will bring us great advice based on his successful experiences on both sides of the Atlantic. Bernard's active involvement on the board gives us a guarantee that our research will remain on track and strengthens our relationships with the international academic community."